Press Release

Morgan Lewis Advises Engage Therapeutics in Sale to UCB

Friday, June 5, 2020

PRINCETON, June 5, 2020: Morgan Lewis represented Engage Therapeutics Inc. in its sale to UCB. The transaction is valued at $125 million in cash (subject to certain adjustments) and up to $145 million in further potential milestone payments related to the clinical development, submission, and launch of Staccato® Alprazolam.

Engage Therapeutics is a clinical-stage pharmaceutical company developing Staccato Alprazolam for the rapid termination of an active epileptic seizure. UCB, based in Brussels, is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to aid individuals living with severe diseases of the immune system or of the central nervous system.

Partners Steve Cohen and Key Shin and of counsel Veronica DiCamillo represented Engage Therapeutics.

For more, read the announcement.